European stocks near week-high as Genmab rises

European stocks rose, near their highest levels in a week, supported by gains in the healthcare sector following positive results from a study on Genmab’s treatment. The study showed that the combination therapy developed by Genmab in partnership with Amgen reduces the risk of disease progression or death in newly diagnosed lymphoma patients. The Stoxx 600 index increased by 0.8%, while Genmab’s shares jumped 7.7%, reaching their highest level in three years. Meanwhile, Eurozone bond yields declined amid rising concerns over high debt levels and political stalemate, impacting expectations for an interest rate hike by the European Central Bank.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل